Canada markets open in 5 hours 42 minutes

Sutro Biopharma, Inc. (S09.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
4.2800+0.3000 (+7.54%)
As of 09:15AM CET. Market open.
Full screen
Previous Close3.9800
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.2800 - 4.2800
52 Week Range1.9100 - 5.6500
Avg. Volume35
Market Cap263.449M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)-2.7000
Earnings DateMar 28, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.71
  • GlobeNewswire

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences. Conference Details: Oppenheimer 34th Annual Healthcare Life Sciences ConferenceDate: February 13-14, 2024Location: Virtual TD Cowen 44th Annual Health

  • GlobeNewswire

    Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

    Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression Promising clinical activity and tolerability of luvelta as both a monotherapy and in combination across multiple cancers may provide for a significant commercial opportunity Investor webcast today at 1:30 p.m. PT / 4:30 p.m. ET S

  • Simply Wall St.

    Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

    Sutro Biopharma, Inc. ( NASDAQ:STRO ) shares have had a really impressive month, gaining 48% after a shaky period...